Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ambarella Inc (AMBA) vs Nuwellis Inc (NUWE) Price & Performance

Ambarella Inc
Nuwellis Inc

Price performance

Price movement over the last 24 hours

Key statistics

Ambarella Inc vs Nuwellis Inc — how do they compare? Ambarella Inc trades at $75.39 (market cap $3.39B), while Nuwellis Inc trades at $2.94 (market cap $1.10M). The key difference: Ambarella Inc is far larger — about 3081.8× Nuwellis Inc's market cap, and Ambarella Inc is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.

AMBANUWE
Market Cap
$3.39B$1.10M
Sector
TechnologyTechnology
52-Week High
$95.51$558.26
52-Week Low
$48.65$2.87
Enterprise Value
$3.13B-$713.47K

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ambarella Inc

Ambarella (AMBA) trades at $77.30, down 1.38% on the day, with a bullish technical setup supported by moving averages and key resistance at $81. The company reported three consecutive quarterly EPS beats, with Q1 2027 earnings of $0.11 meeting estimates, while revenue grew 16.9% year-over-year to $100.4 million. A major catalyst is the $800+ million long-term edge AI agreement with Hanwha, signaling strong demand in physical AI markets. However, net income remains negative at -$117.13 million for 2025, though margins are improving.

Outlook: Wall Street is bullish with a $108.67 consensus price target (40% upside), driven by edge AI adoption and auto sector growth. Risks include persistent losses, competitive pressure from larger chipmakers, and execution challenges in scaling new AI contracts. The stock's valuation at 8.21x sales appears reasonable if revenue acceleration continues, but profitability remains key for sustained gains.

Nuwellis Inc

NUWE trades at $3.04, up 5.56% today, but faces bearish technical signals with oversold RSI readings. The company reported a net loss of $17.52M in 2025 with negative margins, though recent earnings beat expectations in two of the last three quarters. A reverse stock split was executed in June 2026, and new CEO Mike McCormick is focusing on pediatric market expansion.

Outlook remains challenging due to persistent losses and high cash burn, but strategic initiatives in pediatric cardiorenal care and recent FDA engagement offer potential growth. Risks include financial sustainability and competitive pressures. Analyst sentiment is split evenly between Buy and Hold.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Ambarella Inc

Ambarella is a semiconductor company specializing in low-power video compression and computer vision processors. Its chips power AI cameras for security, automotive safety, and robotics applications.

Read more on AMBA

About Nuwellis Inc

Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.

Read more on NUWE